Unlocking migraine relief: Gencor touts latest clinical findings for bioavailable PEA ingredient
09 Feb 2024 --- A recent human clinical trial reveals that Gencor’s palmitoylethanolamide (PEA) ingredient, Levagen+, can help alleviate the discomfort associated with migraine headaches. The study also found that Levagen+ may reduce the duration of migraines in healthy individuals.
Migraines — a prevalent neurological condition predominantly affecting young to middle-aged adults — are more common in females. While several treatment options exist, Gencor highlights that they may have unwanted side effects. These new results show that PEA could be a promising alternative.
“The results of this study further back PEA’s clinically validated benefits for its analgesic and inflammatory properties in addition to its neuroprotective effects,” says R.V. Venkatesh, co-founder and managing director at Gencor. “We are thrilled about the promising results and potential of Levagen+ to support those who suffer from migraine.”
A plethora of applications
These latest findings add to the scientific evidence on the health benefits of Levagen+. Recently, Gencor revealed findings of a study that showed the innovative ingredient can help relieve allergy symptoms. Another showed it can help relieve the symptoms of upper respiratory tract infections.
Moreover, the company highlights that these findings are in addition to the offering’s sports and active nutrition effects.
Known for its ability to support a healthy inflammatory response and its possess analgesic properties, Levagen+ has also been shown to relieve the pain of menstrual cramps.
Latest findings
This latest double-blind, placebo-controlled clinical trial, published in Pharmaceuticals, looks at Levagen+’s efficacy in reducing pain and length of migraine episodes. The study included 80 participants experiencing migraine symptoms. The participants were divided into two groups that were administered either 600 mg of Levagen+ or a placebo in the form of maltodextrin.
Participants recorded their pain levels on a visual analog scale (VAS) every 30 minutes for 4 hours or until the migraine subsided. If the migraine persisted 2 hours post-dose, participants were advised to take a second supplement.
The researchers found that Levagen+ was more effective in resolving headaches compared to the placebo at both the 2-hour and 8-hour marks. Additionally, participants in the Levagen+ group reported lower VAS scores for pain at 1.5 and 4 hours and significantly reduced their use of rescue medication compared to the placebo group.
Leveraging bioavailability
According to the company, Levagen+is the same PEA formulation as classic Levagen, infused with Pharmako Biotechnologies’ LipiSperse delivery technology.
This makes the PEA ingredient highly bioavailable by increasing the absorption rate. Furthermore, Levagen+ has undergone clinical testing for other health benefits. These include joint health, muscle recovery and sleep and relaxation.
Edited by William Bradford Nichols
